Feedback
Settings

Settings

1. WO2006002434 - NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE

PermaLink
Publication Number WO/2006/002434
Publication Date 05.01.2006
International Application No. PCT/US2005/022870
International Filing Date 24.06.2005
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
A61K 31/41 (2006.01)
A61K 31/445 (2006.01)
A61K 31/66 (2006.01)
C07D 401/04 (2006.01)
C07D 401/14 (2006.01)
C07D 413/14 (2006.01)
CPC
C07D 401/04
C07D 401/14
C07D 409/14
Applicants
  • SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929 Philadelphia, PA 19101, US (AllExceptUS)
  • KERNS, Jeffrey, K. [US/US]; US (UsOnly)
  • EDWARDS, Christine; GB (UsOnly)
Inventors
  • KERNS, Jeffrey, K.; US
  • EDWARDS, Christine; GB
Agents
  • KELLERMAN, James, C. ; Glaxosmithkline Corporate Intellectual Property UW2220 709 Swedeland Road, P.O. Box 1539 King of Prussia, PA 19406-0939, US
Priority Data
60/582,65524.06.2004US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE
(FR) NOUVEAUX INDAZOLE CARBOXAMIDES ET LEUR UTILISATION
front page image
Abstract
(EN)
The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to Formula (I), wherein R1 and Z are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKß) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
(FR)
L'invention concerne de nouveaux dérivés d'indazole carboxamide. L'invention concerne plus précisément des composés représentés par la formule générale (I). Dans cette formule générale (I), R1 et Z désignent des éléments décrits ci-dessous. L'invention concerne également des sels de qualité pharmaceutique de ces dérivés. Les composés de l'invention sont des inhibiteurs d'IKK2 et peuvent être utilisés dans le traitement de troubles associés à une activité d'IKK2 (ou bêta IKK), tels que la polyarthrite rhumatoïde, l'asthme et la maladie pulmonaire obstructive chronique (MPOC). Par conséquent, l'invention concerne également des compositions pharmaceutiques comprenant un composé de l'invention. L'invention concerne également des méthodes permettant d'inhiber l'activité d'IKK2 et de traiter des troubles associés, consistant à utiliser un composé de l'invention ou une composition pharmaceutique comprenant un composé de l'invention.
Also published as
AU2005258332
CA2571712
CN101005836
CO06123820
EP1758578
ES2358579
ID047.0732
IL179747
IN7713/DELNP/2006
JP2008504296
KR1020070043940
MXPA/a/2006/014481
NO20070076
NZ551647
PH12006502391
RU2007102576
US20070281933
VN1200602121
VN14290
ZA2006/09759
ZA200609759
Other related publications
AR050253
BRPI0512533
MA28727
MYPI 20052862
PE2006-0373
Latest bibliographic data on file with the International Bureau
# -